XNAS · Healthcare · Biotechnology
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | Q1 2026 | -0.67 | -0.26 | +61.19% | $0 | ✅ Beat | -5.00% | -0.63% | — |
| 2026-03-12 | Q4 2025 | -0.36 | -0.26 | +27.78% | $0 | ✅ Beat | +7.33% | -9.95% | -27.23% |
| 2025-11-06 |
| Q3 2025 |
| -1.23 |
| -0.85 |
| +30.89% |
| $0 |
| ✅ Beat |
| — |
| — |
| — |
| 2025-03-13 | Q4 2024 | -0.08 | -0.08 | +0.00% | $0 | ➖ Inline | -0.40% | +2.92% | -29.65% |
| 2024-03-14 | Q4 2023 | -0.14 | -0.20 | -42.86% | $0 | ❌ Miss | — | — | — |
| 2023-08-10 | Q2 2023 | -0.27 | -0.27 | +0.00% | $0 | ➖ Inline | +1.74% | -0.87% | -14.78% |
| 2023-05-12 | Q1 2023 | -0.32 | -0.30 | +6.25% | $0 | ✅ Beat | +4.68% | +37.87% | +0.85% |
| 2023-03-30 | Q4 2022 | -0.30 | -0.32 | -6.67% | $0 | ❌ Miss | +0.00% | -10.77% | +33.85% |
Showing last 8 quarters.